Cenix Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery

News   Feb 03, 2009

 
Cenix Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery
 
 
 

RELATED ARTICLES

Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing Organization

News

Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..

READ MORE

Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological Aging

News

The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.

READ MORE

Engineering the Gut Microbiome with 'Good' Bacteria May Help Treat Crohn's Disease

News

Researchers have singled out a bacterial enzyme behind an imbalance in the gut microbiome linked to Crohn's disease. Replacement of the offending bacteria with "good" bacteria may offer an effective treatment approach.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE